Saturday, 31 October 2026European Markets

HOFSETH BIOCARE Stock Rises 9% So Far On Friday, Outperforms Market

Loading stream...

At 11:43 EST on Friday, shares of HOFSETH BIOCARE (HBC.OL) surged by 9.83% to close at kr3.24 at 11:43 EST - marking an upward movement from their last closing price at kr2.95. Although still 25.32% below their 52-week high of kr3.95, the increase suggests the stock is moving in an optimistic manner similar to Oslo Bors Benchmark Index_GI as a whole.

About Hofseth BioCare ASA

Hofseth BioCare ASA of Alesund, Norway serves as a provider of pet and consumer health ingredients both within Norway and internationally. Products offered include Brilliant and OmeGo salmon oils as well as ProGo Salmon Protein Powder.

Financial Health Concerns

However, despite HBC.OL's stock rally, its financial health remains cause for serious concern. Over the past year it reported negative earnings per share of kr-0.37 and its return on equity is also disconcertingly negative at 126.49% indicating significant shareholder equity losses.

Stock Stability

On a positive note, however, the value of HOFSETH BIOCARE's shares remains well above its 50-day moving average of kr2.87 and slightly above its 200-day moving average of kr2.96, suggesting relative mid- to long-term stability.

Revenue Growth and Profitability

As well, the company has witnessed impressive revenue growth; its year-on-year quarterly revenue growth increased by 45.4% year over year to reach 134.43 million during its twelve trailing months period. Unfortunately, however, EBITDA stands at a negative number at -39.65; thus raising concerns over its profitability.

Conclusion

Overall, HOFSETH BIOCARE's stock performance indicates an upward trajectory with promising revenue growth and worrying profitability metrics that call attention to the need for strategic decision-making in order to enhance shareholder returns and bolster overall financial status.

More news about HOFSETH BIOCARE (HBC.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com